Instil Bio (TIL) Cash from Financing Activities (2020 - 2025)
Instil Bio (TIL) posted quarterly Cash from Financing Activities of $378000.0 for Q3 2025, up 137.74% year-over-year from $159000.0 in Q3 2024, and down 94.34% quarter-over-quarter from $6.7 million in Q2 2025.
Instil Bio (TIL) Cash from Financing Activities (2020 - 2025) Analysis & Trends
Instil Bio's Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $378000.0 for Q3 2025.
- In Q3 2025, Cash from Financing Activities rose 137.74% year-over-year to $378000.0; the TTM figure through Mar 2026 stood at $7.1 million (up 255.31% YoY), while the FY2025 annual figure was $7.3 million, up 315.5% from the prior year.
- Cash from Financing Activities for Q3 2025 stood at $378000.0, down from $6.7 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $394.7 million in Q1 2021, with the low at -$1.9 million in Q2 2021.
- The 5-year median for Cash from Financing Activities is $987000.0 (2024), against an average of $30.1 million.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities surged 12066.94% in 2022, then plunged 103.99% in 2023.
- Instil Bio's Cash from Financing Activities stood at $198000.0 in 2021, then jumped by 3032.32% to $6.2 million in 2022, then tumbled by 109.46% to -$587000.0 in 2023, then surged by 371.89% to $1.6 million in 2024, then sank by 76.32% to $378000.0 in 2025.
- Business Quant data shows TIL's Cash from Financing Activities at $378000.0 in Q3 2025, $6.7 million in Q2 2025, and $232000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Instil Bio | 51.68 Mn | 51.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 378,000.00 |
| Sep 30, 2025 | 378,000.00 |
| Jun 30, 2025 | 6.68 Mn |
| Jun 30, 2025 | 6.68 Mn |
| Mar 31, 2025 | 232,000.00 |
| Mar 31, 2025 | 232,000.00 |
| Dec 31, 2024 | 1.60 Mn |
| Dec 31, 2024 | 1.60 Mn |
| Sep 30, 2024 | 159,000.00 |
| Sep 30, 2024 | 159,000.00 |
| Sep 30, 2023 | -587,000.00 |
| Sep 30, 2023 | -587,000.00 |
| Jun 30, 2023 | 4.20 Mn |
| Jun 30, 2023 | 4.20 Mn |
| Mar 31, 2023 | 4.47 Mn |
| Mar 31, 2023 | 4.47 Mn |
| Dec 31, 2022 | 6.20 Mn |
| Dec 31, 2022 | 6.20 Mn |
| Sep 30, 2022 | 14.72 Mn |
| Sep 30, 2022 | 14.72 Mn |